Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant

Aaron N. Pham, Joseph Bubalo, James S. Lewis

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

    Original languageEnglish (US)
    Pages (from-to)6945-6947
    Number of pages3
    JournalAntimicrobial Agents and Chemotherapy
    Volume60
    Issue number11
    DOIs
    StatePublished - Nov 1 2016

    Fingerprint

    Hematologic Neoplasms
    Tablets
    Stem Cells
    Transplants
    Hematopoietic Stem Cells
    Serum
    posaconazole
    Therapeutics
    Invasive Fungal Infections

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)
    • Infectious Diseases

    Cite this

    Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant. / Pham, Aaron N.; Bubalo, Joseph; Lewis, James S.

    In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 11, 01.11.2016, p. 6945-6947.

    Research output: Contribution to journalArticle

    @article{2930d6b17daf45308c98a6d2d2a6181b,
    title = "Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant",
    abstract = "We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.",
    author = "Pham, {Aaron N.} and Joseph Bubalo and Lewis, {James S.}",
    year = "2016",
    month = "11",
    day = "1",
    doi = "10.1128/AAC.01489-16",
    language = "English (US)",
    volume = "60",
    pages = "6945--6947",
    journal = "Antimicrobial Agents and Chemotherapy",
    issn = "0066-4804",
    publisher = "American Society for Microbiology",
    number = "11",

    }

    TY - JOUR

    T1 - Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant

    AU - Pham, Aaron N.

    AU - Bubalo, Joseph

    AU - Lewis, James S.

    PY - 2016/11/1

    Y1 - 2016/11/1

    N2 - We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

    AB - We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

    UR - http://www.scopus.com/inward/record.url?scp=84994509551&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84994509551&partnerID=8YFLogxK

    U2 - 10.1128/AAC.01489-16

    DO - 10.1128/AAC.01489-16

    M3 - Article

    C2 - 27600035

    AN - SCOPUS:84994509551

    VL - 60

    SP - 6945

    EP - 6947

    JO - Antimicrobial Agents and Chemotherapy

    JF - Antimicrobial Agents and Chemotherapy

    SN - 0066-4804

    IS - 11

    ER -